Davidorf Eye Group -- Only Los Angeles Site Conducting Clinical Trials with New Dual Optic Introcular Lens

Share Article

Cataract surgery is one of the most commonly performed surgeries (over 2 million per year in the US alone). The major area of innovation for cataract surgery involves the lens designs that are implanted following removal of a cataract. Currently, there are three intraocular lenses (IOLs) approved by the FDA that enable cataract surgery patients both near and far vision without glasses. A fourth IOL, the Synchrony Lens (Visiogen, Inc.) is a completely novel concept for an IOL that can provide a full range of vision -- without glasses. Davidorf Eye Group in West Hills, California, is conducting Synchrony Clinical Trials.

Jonathan Davidorf, MD, and the Davidorf Eye Group is one of only 25 sites in the country, and the only location in the greater Los Angeles area, designated as a principal investigative site for the first dual-optic accommodating lens developed for both cataract and refractive surgery. The Visiogen Synchrony Intraocular Lens (IOL) is designed to enable patients undergoing cataract surgery to see both near and far -- without glasses -- using a dual-optic lens that operates by use of a spring system.

Presbyopia, the inability to focus near, which makes reading without glasses difficult, affects nearly all people by the age of 50. The unique dual-optic design of Synchrony attempts to provide vision at all distances much like a normal functioning lens.

The dual optic lens can be inserted through a 3.6 mm clear-corneal incision. The single-piece silicone lens unfolds in the eye upon insertion and features two optics connected by a spring-system. The silicone springs connect a 5.5-mm high-power anterior optic and a 6-mm negative power posterior optic; the spring action moves the front optic and changes the eye's focus from near to far. This unique combination of positive and negative powered optics is customized for each individual patient.

"The Synchrony IOL is kind of like a telescope -- it adjusts to near and far," says Dr. Davidorf. "The Synchrony lens is the newest option in the growing area of presbyopic correcting lens implants. IOLs are no longer one-size-fits-all. Every patient is different and with greater choices come better options. Patients with cataracts need to be aware of all of their options." Another intraocular lens that has recently won FDA approval in the US is the single optic Crystalens -- which uses silicone hinges to allow the lens to move, or accommodate, to seamlessly focus on objects at a full spectrum of distances.

To undergo implantation with one of the FDA approved IOLs that attempt to correct near and distance vision, patients will pay approximately $2,500 (beyond what their insurance pays). Some patients are unable to afford this. If enrolled in the Synchrony Clinical Trial, the patients receive the latest generation IOL without the extra expense. There are only a limited number of spots in the study. For more information about the clinical study of the Visiogen Synchrony Intraocular Lens and to see if you or someone you know may be a candidate for the study or for other IOLs currently available, please contact the Davidorf Eye Group at 818-883-0112, or visit http://www.davidorf.com.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Daphne Yousem
Visit website